Merck KGaA
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.6M
Doctors Paid
135
Transactions
551
2024 Total
$135,164
Payment Breakdown by Category
Research$2.3M (64.4%)
Consulting$730,219 (20.5%)
Travel$106,706 (3.0%)
Royalty/License$18,000 (0.5%)
Food & Beverage$2,468 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 141 | 64.4% |
| Consulting Fee | $730,219 | 200 | 20.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $409,305 | 117 | 11.5% |
| Travel and Lodging | $106,706 | 67 | 3.0% |
| Royalty or License | $18,000 | 2 | 0.5% |
| Food and Beverage | $2,468 | 24 | 0.1% |
Payments by Type
Research
$2.3M
141 transactions
General
$1.3M
410 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors | $520,736 | 0 | 29 |
| A Phase I Open Label First in Human Dose Escalation and Expansion Study of the Bispecific Anti-Mucin 1 - Epidermal Growth Factor Receptor Antibody Drug Conjugate M1231 as a Single Agent in Participants with Advanced Solid Tumors | $58,888 | 0 | 14 |
| A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | $17,550 | 0 | 7 |
| A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX) | $15,175 | 0 | 22 |
| MS 700568-0002 | $8,010 | 2 | 5 |
| Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | $3,315 | 0 | 6 |
| A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study). | $1,905 | 0 | 3 |
| A Phase I, Two-Part, Multicenter, Open-Label First in Human Study of anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants with Advanced Solid Tumors | $1,627 | 0 | 22 |
| A Phase 1, Two-Part, Multicenter, Open-Label First in Human Study of anti-GD2 Antibody Drug Conjugate M3554 in Participants with Advanced Solid Tumors | $1,223 | 0 | 14 |
| A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high risk for relapse and are ineligible for high-dose cisplatin | $1,184 | 0 | 4 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Neurology | $531,998 | 46 | $11,565 |
| Internal Medicine | $188,618 | 16 | $11,789 |
| Medical Oncology | $167,958 | 14 | $11,997 |
| Hematology & Oncology | $85,588 | 13 | $6,584 |
| Specialist | $51,903 | 4 | $12,976 |
| Radiation Oncology | $39,362 | 4 | $9,841 |
| Obstetrics & Gynecology | $34,688 | 5 | $6,938 |
| Endocrinology, Diabetes & Metabolism | $25,388 | 3 | $8,463 |
| Allergy & Immunology | $13,849 | 1 | $13,849 |
| Otolaryngology | $13,755 | 1 | $13,755 |
| Cardiovascular Disease | $11,138 | 1 | $11,138 |
| Pediatric Infectious Diseases | $11,022 | 1 | $11,022 |
| Ophthalmology | $10,980 | 2 | $5,490 |
| Reproductive Endocrinology | $10,019 | 2 | $5,010 |
| Interventional Cardiology | $8,288 | 1 | $8,288 |
| Physical Medicine & Rehabilitation | $7,014 | 1 | $7,014 |
| Gynecologic Oncology | $5,800 | 4 | $1,450 |
| Psychiatry | $5,750 | 1 | $5,750 |
| Trauma Surgery | $5,746 | 1 | $5,746 |
| Anatomic Pathology & Clinical Pathology | $4,935 | 2 | $2,468 |
| Adult Health | $3,290 | 1 | $3,290 |
| Neuromuscular Medicine | $2,760 | 2 | $1,380 |
| Infectious Disease | $2,720 | 1 | $2,720 |
| Rheumatology | $2,528 | 1 | $2,528 |
| Pediatrics | $2,220 | 1 | $2,220 |
| Gastroenterology | $2,190 | 1 | $2,190 |
| Pediatric Hematology-Oncology | $2,070 | 1 | $2,070 |
| Hematology | $1,725 | 1 | $1,725 |
| Diagnostic Radiology | $1,425 | 1 | $1,425 |
| Urology | $1,035 | 1 | $1,035 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Jeremy Sugarman, M.d, M.D | Internal Medicine | Baltimore, MD | $75,164 | $0 |
| Dr. Bruce Cree, M.d, M.D | Neurology | San Francisco, CA | $54,170 | $0 |
| Ravi Dukkipati, M.d, M.D | Neurology | York, PA | $46,285 | $0 |
| Anthony Reder, Md, MD | Neurology | Burr Ridge, IL | $42,850 | $0 |
| Ezra Cohen, Md, MD | Hematology & Oncology | San Diego, CA | $40,610 | $0 |
| Dr. Mitzi Williams, M.d, M.D | Neurology | Smyrna, GA | $38,574 | $0 |
| Annette Okai, Md, MD | Neurology | Plano, TX | $38,403 | $0 |
| Dr. Joaquin Bellmunt Molins, M.d, M.D | Medical Oncology | Boston, MA | $36,015 | $0 |
| Barry Hendin, Md, MD | Neurology | Phoenix, AZ | $34,949 | $0 |
| Petros Grivas, M.d, M.D | Medical Oncology | Seattle, WA | $34,500 | $0 |
| Dr. Aaron Boster, Md, MD | Neurology | Columbus, OH | $31,579 | $0 |
| Riley Bove, M.d, M.D | Neurology | San Francisco, CA | $28,250 | $0 |
| Dr. Jonathan Schoenfeld, Md, MD | Radiation Oncology | Boston, MA | $27,107 | $0 |
| Mr. Angel Chinea, M.d, M.D | Specialist | Guaynabo, PR | $25,311 | $0 |
| Dr. George Demetri, Md, MD | Medical Oncology | Boston, MA | $25,161 | $0 |
| John Heymach, M.d, M.D | Internal Medicine | Houston, TX | $22,656 | $0 |
| Dr. Beverly Biller, Md, MD | Internal Medicine | Boston, MA | $21,545 | $0 |
| Xiuning Le, M.d, M.D | Specialist | Boston, MA | $20,158 | $0 |
| Ann Bass, M.d, M.D | Neurology | San Antonio, TX | $17,900 | $0 |
| Dr. Jacqueline Nicholas, M.d, M.D | Neurology | Columbus, OH | $15,910 | $0 |
| Anne Cappola, Md, MD | Endocrinology, Diabetes & Metabolism | Philadelphia, PA | $15,178 | $0 |
| Dr. Paul Paik, Md, MD | Internal Medicine | New York, NY | $14,766 | $0 |
| Dr. Maria Houtchens, Md, MD | Neurology | Brookline, MA | $14,160 | $0 |
| Staley Brod, M.d, M.D | Neurology | Milwaukee, WI | $14,017 | $0 |
| Dr. Wanda Phipatanakul, Md, Ms, MD, MS | Allergy & Immunology | Boston, MA | $13,849 | $0 |
Ad
Top Products
- M6223 and Bintrafusp alfa $518,210
- MSC2571458 $280,800
Associated Products (4)
- M6223 and Bintrafusp alfa $518,210
- MSC2571458 $280,800
- immunoproteasome inhibitors $206,489
- Erbitux $24,709
Payment Categories
- Food & Beverage $2,468
- Consulting $730,219
- Travel & Lodging $106,706
- Research $2.3M
- Royalties $18,000
About Merck KGaA
Merck KGaA has made $3.6M in payments to 135 healthcare providers, recorded across 551 transactions in the CMS Open Payments database. In 2024, the company paid $135,164. The top product by payment volume is M6223 and Bintrafusp alfa ($518,210).
Payments were distributed across 30 medical specialties. The top specialty by payment amount is Neurology ($531,998 to 46 doctors).
Payment categories include: Food & Beverage ($2,468), Consulting ($730,219), Research ($2.3M), Travel & Lodging ($106,706), Royalties ($18,000).
Merck KGaA is associated with 4 products in the CMS Open Payments database, including M6223 and Bintrafusp alfa, MSC2571458, and immunoproteasome inhibitors.